- Gatti strikes again to send Juventus top
- France's Le Pen ordered to stand trial in EU funding scandal
- Life sentence for Michigan teen who shot dead four classmates
- US vetoes Security Council resolution calling for Gaza ceasefire
- US vetoes UN ceasefire bid as battles rage across Gaza
- Frenchman Nancy's journey reaches MLS summit
- Led by Taylor Swift's $1 bn tour, 2023 concerts set new record
- Mexico leader proposes referendum on bull fighting in capital
- Battles rage across Gaza as UN holds rare vote
- DAY TWO OF HONG KONG INVESTOR SUMMIT TACKLES MEGATRENDS IMPACTING THE PLANET'S EIGHT BILLION CITIZENS
- 'Appetite for drumsticks': First prey found in a tyrannosaur stomach
- Oil at the root of Guyana-Venezuela border row
- US, UK, Canada sanction dozens on human rights anniversary
- Pope prays for victims of oppression at Christian festival
- The Pogues singer-songwriter Shane MacGowan given full Irish send-off
- USA and Mexico submit bid to host 2027 Women's World Cup
- Stellantis warns thousands in US of potential job cuts
- Real Madrid boss Ancelotti expecting Vinicius to return in January
- Spurs won't compromise on attacking football, says Postecoglou
- Rent-a-tree firm helps Londoners have a sustainable Christmas
- Harvard president apologizes for remarks on campus anti-Semitism
- Wall Street stocks shrug off strong jobs data
- Hamas brutality doesn't justify 'punishment' of Palestinians: UN chief
- Rent-a-tree firm helps Londoners have a sustaintable Christmas
- From Obiang to Putin: the world's longest-serving leaders
- Department of Defense Awards 6K Additive a $23.4 million Grant as Part of a More Than $50 Million Investment Program for Upcycling Critical Metals for...
- Battles rage across Gaza ahead of rare UN vote
- OrangeX Unveils $5M Innovation Fund, Accelerating Support for Bitcoin Ecosystem Growth
- UN Security Council meets on escalating Guyana-Venezuela row
- US unemployment ticks down as job market remains robust
- Hamas brutality can't justify 'collective punishment' of Palestinians: UN chief
- Pochettino says pressure at Chelsea is 'massive' but future bright
- The 2023 Global Investment Promotion Conference Held in Shenzhen, China
- UN talks look for deal on winding down fossil fuels
- Guardiola says Man City have been handed brutal reality check
- HH Global discloses environmental impact through CDP
- IOC clears Russians to compete in Paris as neutrals
- Pensana Plc - Report on Payments to Governments for FY 2023
- Once the bane of big tech, Vestager's star wanes
- Strong US jobs data weakens Wall Street stocks
- New trains, new tracks: US rail to get much-needed facelift
- Meinhardt MENA, Innovo, and Schneider Electric Join Forces to Drive Sustainable Energy Practices in the UAE
- US unemployment ticks down as hiring accelerates
- Miami International Holdings Reports November 2023 Trading Results; YTD Options and Equities Volumes Remain at Record Levels
- Krispy Kreme doughnuts, the latest US chain to try its luck in France
- Third Point Investors Ltd - Weekly Estimate Net Asset Value - December 2023
- Rashford must fight for Man Utd place, says Ten Hag
- Klopp happy with Liverpool's progress after team rebuild
- K2 Corporate Mobility embarks on an incredible expedition to Nepal, trekking to Everest Base Camp and volunteering at Nepalese schools
- Marula Mining Plc - Exercise of Warrants Director, PDMR Shareholding
US authorizes first condom for use in anal sex
The US Food and Drug Administration (FDA) on Wednesday authorized the first condom for use during anal intercourse, in what was hailed as a victory for sexual health by experts.
Although people already use condoms for anal sex -- as is recommended by health agencies including the Centers for Disease Control and Prevention (CDC) -- regulators across the world had only previously allowed companies to officially market their products as "safe and effective" for vaginal use.
Sexual health advocates considered this an unmet public health need since unprotected anal intercourse carries the greatest risk of HIV transmission via sexual exposure, with one study finding that 69 percent of men who have sex with men would use condoms more frequently if they were FDA-indicated.
Wednesday's authorization of Global Protection Corp's One Male Condom follows a clinical trial involving more than 500 people, carried out by Emory University.
"The FDA's authorization of a condom that is specifically indicated, evaluated and labeled for anal intercourse may improve the likelihood of condom use during anal intercourse," said agency scientist Courtney Lias in a statement.
The condom is also indicated to prevent sexually transmitted infections -- and as a contraceptive -- during vaginal sex.
"We want people to have lots of sex -- but we also want them to be empowered and informed," said Davin Wedel, president of Global Protection Corp, which makes the condom brand that is available in 54 sizes, and incorporates a paper template to help each user find the right size.
The clinical trial involved 252 men who have sex with men and 252 men who have sex with women, aged between 18 and 54.
The FDA had said it would accept a five percent failure rate, which previous trials had failed to accomplish. The limit was easily surpassed in the new study, with the failure rate 0.68 percent for anal and 1.89 percent for vaginal intercourse.
The researchers behind the study, which was published in The Lancet's eClinicalMedicine, said one of the reasons the trial succeeded where others failed in the past was likely due to the provision of lubricant and inclusion of instructions on how to use the product.
Lubricant reduces friction, which in turn causes condom failure from slippage and breakage.
Another reason could be that participants were asked to keep mobile phone-based daily diaries, whereas past trials had asked volunteers to recall failure events up to several months later.
Monica Gandhi, an infectious disease doctor and medical director of an HIV clinic in San Francisco, welcomed the finding.
"The important thing about condoms is they don't just prevent HIV, but they prevent gonorrhea, chlamydia and syphilis," she told AFP, adding it was surprising that such an authorization had taken so long to achieve.
In its statement, the FDA said the green light could pave the way for more makers to apply for similar authorization if they show equivalent results.